ProQR Therapeutics NV (PRQR)
1.79
-0.01
(-0.56%)
USD |
NASDAQ |
Jun 13, 16:00
1.79
0.00 (0.00%)
After-Hours: 20:00
ProQR Therapeutics Revenue (Quarterly): 4.834M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.834M |
| December 31, 2023 | 3.537M |
| September 30, 2023 | 1.492M |
| June 30, 2023 | 1.314M |
| March 31, 2023 | 0.7035M |
| December 31, 2022 | 0.7362M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.82M |
| June 30, 2022 | 0.9906M |
| March 31, 2022 | 1.268M |
| December 31, 2021 | 0.2516M |
| September 30, 2021 | 1.028M |
| June 30, 2021 | 0.2929M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.2516M
Minimum
Dec 2021
4.834M
Maximum
Mar 2024
1.439M
Average
1.009M
Median
Revenue (Quarterly) Benchmarks
| uniQure NV | 8.485M |
| Merus NV | 7.889M |
| argenx SE | 401.00M |
| Pharming Group | 55.59M |
| Pharvaris NV | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.318M |
| Total Expenses (Quarterly) | 13.60M |
| EPS Diluted (Quarterly) | -0.0978 |
| Enterprise Value | 40.79M |
| Profit Margin (Quarterly) | -172.1% |
| Earnings Yield | -20.02% |
| Normalized Earnings Yield | -22.65 |